ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-B7-H3/Anti-PTK7-TOP1i Bispecific Antibody-drug Conjugate IDE034

Its studies are mostly in Esophageal Squamous Cell Carcinoma, led by IDEAYA Biosciences.

Furthest: phase 1, since Mar 19, 20261 company-led study, 1 open or runningNext primary completion: Jul 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
IDEAYA Biosciences11 open or runningphase 1since Mar 19, 2026Mar 19, 2026Jul 30, 2027phase 1 · NCT07503808

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 19, 2026First study: phase 1 study in Esophageal Squamous Cell CarcinomaFirst studyNCT07503808 · 150 planned · United States, Georgia, Spain

Ahead

  1. Jul 30, 2027Primary completion: phase 1 study in Esophageal Squamous Cell CarcinomaNCT07503808

TargetBeta

CD276 →PTK7 →read by rule
“An antibody-drug conjugate (ADC) composed of a bispecific antibody directed against the tumor associated antigens (TAAs) B7-homologue 3 (B7-H3, CD276) and human inactive tyrosine-protein kinase 7 (protein tyrosine kinase 7; PTK7) that is ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07503808Esophageal Squamous Cell Carcinoma · United States, Georgia, Spain1RecruitingJul 30, 2027150

How it is read

Names in the registry

  • “IDE034”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.